SCHEMBL30228312

SCHEMBL30228312

COC(=O)/C=C(\C)c1ccc2c(-c3ccccc3C)cc(=O)oc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNA3 P22001 3/20 0.46
▸ CA9 Q16790 4/20 0.40
▸ CA12 O43570 3/20 0.40
▸ ALDH1A1 P00352 7/20 0.40
▸ HPGD P15428 4/20 0.40
▸ USP2 O75604 1/20 0.40
▸ GAA P10253 3/20 0.40
▸ KDM4E B2RXH2 3/20 0.40
▸ GLA P06280 2/20 0.40
▸ MAPT P10636 2/20 0.40
▸ NPBWR1 P48145 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ CA1 P00915 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ OPRK1 P41145 1/20 0.39
▸ NPC1 O15118 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ AR P10275 1/20 0.38
▸ POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30228438 0.82 KCNA3 (0.59) KCNA3CA9CA12ALDH1A1HPGD
SCHEMBL30227982 0.80 KCNA3 (0.55) KCNA3CA9CA12ALDH1A1HPGD
SCHEMBL30228284 0.79 KCNA3 (0.52) KCNA3CA9CA12ALDH1A1HPGD
SCHEMBL30228199 0.79 KCNA3 (0.50) KCNA3CA9CA12ALDH1A1KDM4E
SCHEMBL30228546 0.77 KCNA3 (0.52) KCNA3CA9CA12ALDH1A1HPGD
SCHEMBL30228398 0.76 NPC1 (0.51) KCNA3ALDH1A1HPGDGAAKDM4E
SCHEMBL31731468 0.75 KDM5A (0.39) ALDH1A1KMT2ACYP1A2
SCHEMBL30228274 0.75 CA12 (0.70) KCNA3CA9CA12ALDH1A1HPGD
SCHEMBL30231784 0.74 KDM4E (0.67) KCNA3CA9CA12ALDH1A1HPGD
SCHEMBL22431749 0.73 CA12 (0.70) KCNA3CA9CA12ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250326732-A1 CHROMEN-2-ONE MODULATORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2025-10-23 — — US disclosed
WO-2023034346-A1 CHROMEN-2-ONE MODULATORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2023-03-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250326732-A1 CHROMEN-2-ONE MODULATORS OF POLRMT POLRMT, TFAM, POLM KCNA3 4258/4885CA9 4824/4885CA12 4755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback